Evolution of Chronic Kidney Disease: Defining a Model for Care
World Congress of Nephrology (ASN/ISN), San Francisco, CA, October, 2001
A Welcome and Introductory Remarks
Moderator (Paul Kimmel, MD):
I'd like to welcome you. Please continue your dinner. My name is Paul Kimmel from George Washington University. I am here to welcome you to this World Congress of Nephrology official symposium today on "The Evolution of Chronic Kidney Disease: Defining a Model For Care."
This is a special symposium because it is a joint effort of the American Society of Nephrology and Ortho Biotech Products, L.P. We're very excited about this program. As I can see by your attendance, you are as well. I think we'll try to have a very quick set of presentations, 20 minutes a speaker, and we'll have a half hour for questions at the end of the presentation.
Now I would like to introduce Dr. Ajay Singh, who is the Clinical Director of the renal division and the Director of Dialysis at the Brigham and Women's Hospital in Boston, Massachusetts, and Associate Professor of Medicine at Harvard Medical School.
Ajay K. Singh, MD:
Thanks Paul. I would like to also welcome you. This is a very important area nowadays. It's an area that we all read about and certainly practice in our offices. What we're going to do is have a very exciting program for you.
The Ten A's of CKD
When we look into management of chronic kidney disease in 2001, I think we would all agree that it's a multidisciplinary effort with a long list of problems that we often have to grapple with. Each one of you has your own mental list of problems that you click off as you see patients in the office. This is my own list. The purpose of showing you this slide is just to show you that there are so many issues that we deal with when we see patients with chronic kidney disease.
Today, what we're going to do is probably focus most of our attention on anemia because it's certainly a very important area. It's a very important topical area, as well as being something that's treatable. But I just want to emphasize to you that this does not mean that we don't consider any of these other areas important. This meeting of the World Congress of Nephrology has addressed many of these issues.
The objectives of this evening's program are threefold: prevalence and current treatment of chronic kidney disease, optimizing anemia management in patients with chronic kidney disease, and then this very vexing issue about correcting mild anemia in severe resistant CHF and showing how this has an important impact on cardiorenal function. To introduce the first speaker, Dr. Kimmel is going to come back to the microphone.
This educational activity is supported by an educational grant from Ortho Biotech Products, L.P.
This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.
This educational activity is based on an ASN/ISN evening symposium which was
planned by the World Congress of Nephrology program committee.